PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
Some people see significant hair regrowth using treatments like finasteride and minoxidil, while others experience little to no improvement even with comprehensive treatment plans. Factors such as individual sensitivity to DHT may influence the effectiveness of these hair loss treatments.
A 33-year-old male is thrilled with his hair transplant results one year post-procedure, having used 1 mg finasteride and 2.5 mg oral minoxidil daily, which significantly improved his hair density. The transplanted hair is expected to be permanent, but continued use of finasteride is recommended to maintain surrounding native hair.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
A user is using homemade topical spironolactone for androgenetic alopecia and is unsure about its effectiveness due to concurrent telogen shedding. They are seeking advice on others' experiences with homemade topical spironolactone.
A user shared their positive experience with a 2,600 grafts hair transplant surgery in India, expressing optimism about the results. The conversation also debated the necessity of medications like finasteride to maintain hair transplant results and prevent further hair loss.
A medical student experienced hair loss slowing with Finasteride but developed severe, treatment-resistant insomnia. They tried various medications with little effect, suspecting Post-Finasteride Syndrome, and others suggested the insomnia might be linked to Finasteride's impact on neurosteroids.
Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.
A user's plan to use Zix and topical finasteride (5AR inhibitors) for hair loss, followed by blood testing before/after. The user has suggested creating a fund to cover part of the cost of their blood tests. Replies to their post discuss the effectiveness of the treatments.
The user is experiencing chest sensitivity and muscle ache after using topical finasteride for a month and is concerned about potential gynecomastia. They are considering asking their doctor for blood work to check estrogen levels and are questioning whether to stop using finasteride.
After a year on dutasteride and oral minoxidil, the user experienced significant hair regrowth, improving from Norwood 2 to almost Norwood 1. They added RU58841, microneedling, rosemary oil, GHK-Cu, and annurca apple supplement to their regimen and are now noticing hair loss in the temple area.
The user is considering switching from oral to topical minoxidil due to lack of improvement and side effects, while continuing with dutasteride or finasteride. They seek advice from others with diffuse thinning.
A user's 3-month progress on minoxidil and finasteride, getting amazing results and offering advice to others considering the treatments. Replies include other users sharing their own successes with these treatments and encouraging EmptyPin to keep it up.
A 20-year-old male is experiencing worsening diffuse thinning despite using topical minoxidil, topical finasteride with minoxidil, oral finasteride, stemoxydine, and pyrilutimide. He is seeking support and advice as he struggles with the mental and physical challenges of hair loss treatments.
The user has been on finasteride for over two years, experiencing early hair regrowth, acne, and scalp sensitivity, but now faces thinning hair and questions about dosage and long-term effectiveness. They also used retinal to help with acne and are seeking advice on whether to adjust their finasteride dose.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
The user started using 1mg oral finasteride a year ago and added oral minoxidil 3-4 months ago, experiencing no side effects except initial aching. They found oral minoxidil more effective for regrowth and easier than topical due to its toxicity to dogs.
User started finasteride in Oct 2021 and experienced reduced shedding and side effects. Saw improvements in months 3-5, but worsening in months 11-13, and asks for advice on next steps.
The user experienced almost no improvement in hair loss after 3 months using microneedling, RU58841, sulforaphane, finasteride, and dutasteride, especially after stopping minoxidil. They believe minoxidil is more effective than RU58841.
The user is experiencing progressive hair thinning despite using finasteride and dutasteride. A biopsy confirmed male pattern baldness, and minoxidil was suggested as an additional treatment.
The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.
The conversation is about someone experiencing hair regrowth after using finasteride (1mg) for six months, minoxidil 5% for five months, and microneedling twice a week. Respondents agree there is noticeable improvement in hair growth.
The user used minoxidil 5% and finasteride 0.1% for six months, along with a dermaroller and Nizoral shampoo, experiencing only dry scalp as a side effect. They are pleased with the results.
Scalp tension potentially affecting hair loss, and potential treatments for male pattern baldness such as Minoxidil, Finasteride and RU58841. Evidence from a study was discussed which suggests that the cause of MPB lies within the follicle itself and is not dependent on its surrounding environment.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
The user observed new tiny white hairs after 12 days of using minoxidil, finasteride, microneedling, and biotin, hoping they will become terminal hairs. Others advise that while some hairs may not fully grow, consistent treatment, patience, and scalp massages could enhance results.